Several brokerages have updated their recommendations and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) in the last few weeks:

  • 9/14/2018 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/14/2018 – Sarepta Therapeutics is now covered by analysts at Bank of America Corp. They set a “buy” rating and a $199.00 price target on the stock.
  • 9/6/2018 – Sarepta Therapeutics is now covered by analysts at Credit Suisse Group AG. They set an “outperform” rating and a $178.00 price target on the stock.
  • 9/4/2018 – Sarepta Therapeutics was given a new $267.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/24/2018 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/16/2018 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/14/2018 – Sarepta Therapeutics is now covered by analysts at Citigroup Inc. They set a “buy” rating on the stock.
  • 8/9/2018 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $178.00 price target on the stock.
  • 8/9/2018 – Sarepta Therapeutics was given a new $267.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/1/2018 – Sarepta Therapeutics was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $163.00 price target on the stock.
  • 7/27/2018 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

SRPT traded down $0.91 on Tuesday, reaching $151.44. The stock had a trading volume of 4,248 shares, compared to its average volume of 826,413. Sarepta Therapeutics Inc has a fifty-two week low of $42.97 and a fifty-two week high of $176.50. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62. The stock has a market cap of $10.15 billion, a PE ratio of -92.34 and a beta of 1.30.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The firm had revenue of $73.53 million during the quarter, compared to analyst estimates of $71.53 million. During the same period in the previous year, the company earned ($0.48) EPS. Sarepta Therapeutics’s revenue for the quarter was up 110.0% on a year-over-year basis. equities research analysts expect that Sarepta Therapeutics Inc will post -3.69 EPS for the current year.

In related news, CEO Douglas S. Ingram purchased 16,000 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The stock was bought at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the completion of the purchase, the chief executive officer now owns 399,250 shares in the company, valued at approximately $50,010,055. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP David T. Howton sold 50,000 shares of the stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $136.46, for a total value of $6,823,000.00. Following the completion of the sale, the senior vice president now directly owns 37,967 shares of the company’s stock, valued at approximately $5,180,976.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 158,782 shares of company stock valued at $21,237,444. Insiders own 7.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Rockefeller Capital Management L.P. acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $185,000. Keybank National Association OH acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $206,000. Kovack Advisors Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $217,000. Finally, Clarus Wealth Advisors acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $124,000. 90.00% of the stock is owned by institutional investors.

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: Short Selling Stocks and Day Traders

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.